Corcept Therapeutics (CORT) Change in Cash (2010 - 2026)

Corcept Therapeutics has reported Change in Cash for 17 years, with the latest figure at $2.3 million in Q2 2026.

• Quarterly Change in Cash fell 82.2% year-over-year to $2.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.3 million (up 132.09% YoY) and the FY2025 annual result came in at -$7.2 million, up 9.08% from the prior year.
• Change in Cash advanced to $2.3 million in Q2 2026 per CORT's latest filing, from -$11.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $233.6 million in Q1 2023 and troughed at -$127.6 million in Q2 2023.
• A 5-year average of $1.9 million and a median of -$1.2 million in 2025 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2023: Change in Cash soared 2107.68% in 2022, then sank 506.64% in 2023.
• Over 5 years, Change in Cash stood at $16.1 million in 2022, then surged by 47.65% to $23.8 million in 2023, then tumbled by 140.52% to -$9.6 million in 2024, then surged by 51.76% to -$4.6 million in 2025, then soared by 149.56% to $2.3 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $2.3 million, -$11.8 million, and -$4.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.